Amgen Inc. and Axsome Therapeutics, Inc.: SG&A Spending Patterns Compared

A Tale of Two Biotechs: SG&A Spending Trends

In the dynamic world of biotechnology, understanding financial strategies is crucial. Amgen Inc., a stalwart in the industry, and Axsome Therapeutics, Inc., a rising star, offer a fascinating study in contrasts through their Selling, General, and Administrative (SG&A) expenses from 2014 to 2023. Over this period, Amgen's SG&A expenses have shown a steady increase, peaking at approximately 6.2 billion in 2023, reflecting a 31% rise from 2014. This growth underscores Amgen's commitment to maintaining its market leadership through strategic investments.

Conversely, Axsome Therapeutics has experienced a dramatic surge in SG&A spending, skyrocketing from a modest 1.4 million in 2014 to over 323 million in 2023. This exponential increase, over 23,000%, highlights Axsome's aggressive expansion strategy as it seeks to establish a foothold in the competitive biotech landscape. These spending patterns reveal the distinct paths these companies are taking in their quest for innovation and market dominance.